SEC Form 4												
FORM 4	UNITED ST	ATES SECURITIES AND EXCHANGE CON Washington, D.C. 20549	MISSION		ROVAL							
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).		ENT OF CHANGES IN BENEFICIAL OWNI iled pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	ERSHIP	OMB Number: Estimated average bu hours per response:	3235-0287 Irden 0.5							
1. Name and Address of Reporting Perso <u>Flynn James P</u>	on [*]	2. Issuer Name and Ticker or Trading Symbol <u>MEI Pharma, Inc.</u> [MEIP]	5. Relationship of F (Check all applicab X Director	,								
(Last) (First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/18/2023	Officer (gi below)	ve title Othe belo	er (specify w)							
C/O MEI PHARMA, INC. 11455 EL CAMINO REAL, SUIT	ГЕ 250	4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	or Joint/Group Filing (Check Applicable m filed by One Reporting Person								
(Street) SAN DIEGO CA	92130	_	Form filed Person	I by More than One Re	eporting							
(City) (State)	(Zip)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Institutional Conditions of Rule 10b5-1(c).		r written plan that is inter	nded to							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												

1. Title of Security (Instr. 3)	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(1150.4)

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Derivati Securiti Acquire (A) or Dispose of (D) (I	Derivative (Month/Day/Year) Securities Acquired			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$6.33	12/18/2023		A		6,700		(1)	12/18/2033	Common Stock	6,700	\$0	6,700	D	
Stock Option (Right to Buy)	\$6.33	12/18/2023		A		10,000		(2)	12/18/2033	Common Stock	10,000	\$0	10,000	D	

Explanation of Responses:

1. Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date.

2. Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

/s/ Justin J. File, as attorney in 12/20/2023 fact

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date